Troubled Intercell in talks with private equity; Sequencing unveils key prostate cancer triggers;

 @FierceBiotech: Novartis seeking approval for NVA237 for smoker's cough after trials showed it helped patients breathe more easily. News | Follow @FierceBiotech

 @RyanMFierce: Seconded MT @JKureczka: Visit New Zealand exhibitors at #AdvaMed2011 to hear about new government policies for streamlined approvals. | Follow @RyanMFierce

 @MaureenFierce: Reading: Predicting tox on a chip? DARPA soliciting proposal, could award 5 years of funding. Story | Follow @MaureenFierce

 @FierceMedDev: Mazzo: adding more funding won't address problems at FDA. Fundamental issues won't be addressed by throwing money at problem. #AdvaMed2011 | Follow @FierceMedDev

> The troubled Austrian biotech Intercell AG is reportedly in talks with private equity groups interested in taking a stake in the company. Report

> San Mateo, CA-based NeurogesX says Chief Medical Officer Jeffrey Tobias resigned. The biotech has launched a search for his replacement. Release

> The UK's Circassia says it rounded up positive phase II clinical results demonstrating that its ToleroMune hay fever vaccine "substantially improved patients' allergy symptoms compared with those on placebo." Release

> Silence Therapeutics reports that it inked an RNAi collaboration deal with an unnamed pharma company. No financial details were reported. Release

Pharma News

@FiercePharma: Turns out that fixing Genzyme's manufacturing woes is proving tougher than Sanofi thought. Item | Follow @FiercePharma

> Merck chooses ex-Lenovo exec to lead strategy. Report

> FDA turns to advisory panel for Yaz safety analysis. Report

> No consolation for Sanofi as Genzyme scrambles. Article

Pharma Manufacturing News

> Bayer, union at odds over outsourcing promised jobs. Report

> Barcode is India's choice of track/trace weapon. Story

> Taiwan take-down nets fakes-makers, retailers. Report

> Drug in regulatory limbo a headache for Shire, FDA. Piece

> Merck, MedImmune deal space. More

Biotech Research News

> Fred Hutch sequencing project unveils key triggers for prostate cancer. Item

> NIH buddies with Afraxis to escort Fragile X program through "valley of death". Article

> Johns Hopkins researcher designs self-destruct switch for cancer cells. Report

> Sequencing leaders want industry standards to govern decoded DNA. More

And Finally... Some researchers at the prestigious Fred Hutchinson Cancer Research Center allied with scientists at the University of Washington have helped illustrate just how significant sequencing can be for drug discoverers. They've sequenced the genes at play in the genome of prostate cancer at its most lethal stage and found some of the accelerators that drive disease progression. They also report that they've found "hypermutations" which they say can help identify patients resistant to androgen-blocking drugs as well as castration therapy. Report

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.